SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences: Needham Virtual Healthcare ConferenceApril 9, 20241:30 p.m. ET – fireside chat Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 15, 20241:00 p.m. ET – panel discussion A simultaneous webcast of each event will be available on the Inves

Nkarta stock surged Monday — partially reversing a 31% dive on Friday — after unveiling promising test results for its lymphoma treatment.

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for

Aligns with EPS Projections, Prioritizes NKX019 in Autoimmune Diseases Over NKX101

Top-notch Nkarta stock tumbled Friday after the biotech company deprioritized a cancer drug in favor of an experimental lupus treatment.

First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletionAdditional B-cell mediated autoimmune diseases under consideration for broader clinical investigation of NKX019Pipeline realignment focuses resources on rapid advancement of NKX019 in autoimmune diseases and deprioritizes development of NKX1012023 year-end cash, cash equivalents and investments of $250.9 million Cash runway anticipated to fund operations into

Some overlooked stocks remain obscure and wait for astute investors to spot them. This happens even in the middle of Wall Street’s busy trading floors and the digital chaos of online investing platforms. Within the rapidly evolving banking industry, where the newest market darlings often make headlines, three unsung heroes are discreetly laying the groundwork for their rise to fame. All three companies are on the verge of something extraordinary—the first with its unwavering dedication to client

Among tech investments, the search for the next titan resembles a deep dive into the ocean for pearls. The periodic portfolio shifts toward solid tech contenders with high-yield potential as the digital space evolves. From cybersecurity advancement to disruptive biotech, potential brims for astronomical growth through three decisive picks. The first one’s strategic edge, the second one’s steadfast growth trajectory, and the third’s medical breakthroughs offer massive return potential. In short,

The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are making waves in various industries, offering the chance to capitalize on their leads. Read more to delve into the strategies of seven such small-cap stocks poised to skyrocket in value. From the first revolutionizing financial services for the underbanked to the second groundbreaking partnership in

In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready to soar to heights unimaginable to many investors. Amid the cacophony of market chatter are three stocks that stand out: each carves a niche in its respective industry. Each is carving a niche in their respective industries. From revolutionizing convenience store experiences to pioneering breakthrou